ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -41.55% | -32.59% | 7.89% | 39.72% | 132.72% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -46.01% | -44.01% | -15.95% | 4.25% | 71.06% |
Operating Income | 46.01% | 44.01% | 15.95% | -4.25% | -71.06% |
Income Before Tax | 77.92% | 77.59% | -574.65% | -624.75% | -769.44% |
Income Tax Expenses | 93.89% | 93.89% | -369.19% | -1,169.08% | -- |
Earnings from Continuing Operations | 76.20% | 75.86% | -601.11% | -596.03% | -685.30% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 76.20% | 75.86% | -601.11% | -596.03% | -685.30% |
EBIT | 46.01% | 44.01% | 15.95% | -4.25% | -71.06% |
EBITDA | 46.03% | 44.03% | 15.96% | -4.25% | -71.13% |
EPS Basic | 96.24% | 95.17% | -392.17% | -581.30% | -559.49% |
Normalized Basic EPS | 94.07% | 86.20% | 44.60% | -130.01% | -124.00% |
EPS Diluted | 96.24% | 95.17% | -392.17% | -581.30% | -559.49% |
Normalized Diluted EPS | 94.07% | 86.20% | 44.60% | -130.01% | -124.00% |
Average Basic Shares Outstanding | -97.09% | -98.06% | -98.91% | -99.57% | 848.73% |
Average Diluted Shares Outstanding | -97.09% | -98.06% | -98.91% | -99.57% | 848.73% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |